Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22836690 | 0.70 | PIM1 (0.34) | LRRK2 | |
| SCHEMBL22836491 | 0.70 | CDK1 (0.33) | — | |
| SCHEMBL22194226 | 0.66 | HPGD (0.37) | — | |
| SCHEMBL31210989 | 0.66 | — | — | |
| SCHEMBL1982946 | 0.66 | PKM (0.34) | LRRK2 | |
| SCHEMBL22836866 | 0.65 | CCNC (0.32) | LRRK2 | |
| SCHEMBL31276647 | 0.65 | CNR1 (0.38) | LRRK2 | |
| SCHEMBL22111446 | 0.65 | LRRK2 (0.33) | LRRK2 | |
| SCHEMBL22835090 | 0.64 | MAP3K12 (0.38) | LRRK2 | |
| SCHEMBL22105478 | 0.61 | FFAR4 (0.36) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585609-B | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114585609-A | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3990432-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | LRRK2 1097/4885IKBKB 15/4885CHUK 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.